Castle Biosciences, Inc. (CSTL) NASDAQ
25.56
+0.24(+0.95%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
25.56
+0.24(+0.95%)
Currency In USD
Address
505 South Friendswood Drive
Friendswood, TX 77546
United States of America (the)
Phone
866 788 9007
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
784
First IPO Date
July 25, 2019
| Name | Title | Pay | Year Born |
| Derek J. Maetzold | Founder, Chief Executive Officer, President & Director | 1.66M | 1962 |
| Tobin W. Juvenal | Chief Commercial Officer | 883,192 | 1961 |
| Frank Stokes | Chief Financial Officer & Treasurer | 926,744 | 1970 |
| Kristen Oelschlager | Chief Operating Officer | 1.21M | 1968 |
| Jay Braxton | VP of Marketing & Brand Manager of Uveal Melanoma (UM) | 0 | N/A |
| Matthew Goldberg | Senior Vice President of Medical | 0 | N/A |
| Kevin Doman | Vice President of Sales | 0 | N/A |
| Camilla Zuckero | Vice President of Investor Relations & Corporate Affairs | 0 | N/A |
| Keli Greenberg | Vice President of Human Resources | 0 | N/A |
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.